REGISTRATION DOCUMENT 2017 Sommaire

Total Page:16

File Type:pdf, Size:1020Kb

REGISTRATION DOCUMENT 2017 Sommaire REGISTRATION DOCUMENT 2017 sommaire Interview with History 4 Yves L’Épine, Chief Executive Officer 2 Key figures 6 1 4 THE GUERBET GROUP 9 MANAGEMENT REPORT 55 1.1 History of the Company 9 4.1 Analysis of the Group’s activity and results 55 1.2 Mission and ambition 10 4.2 Major events since the start of 2018 58 1.3 Main consolidated data 10 4.3 Information about internal control 59 1.4 Overview of activities 11 4.4 Risk management and risk factors 60 1.5 Industrial and logistics activity 17 4.5 Other legal information 64 1.6 Research and Development 18 1.7 The Group’s governance structure at December 31, 2017 22 5 CORPORATE SOCIAL RESPONSIBILITY 69 2 Employee information 70 CORPORATE GOVERNANCE 27 5.1 5.2 Environmental information 76 2.1 Report of the Board of Directors on 5.3 Social information 80 corporate governance 27 5.4 Report by one of the Statutory Auditors, 2.2 Board of Directors 27 designated as an independent third-party, 2.3 General Management 38 on the consolidated human resources, 2.4 Compensation of company officers 38 environmental and social information 2.5 Agreements referred to in Article L. 225- included in the management report 82 37-4-2° of the French Commercial Code 45 2.6 Provisions in the articles of association 6 relating to General Meetings of Shareholders 46 FINANCIAL STATEMENTS 2.7 Deviations from the recommendations for the composition of the Board of AND RELATED NOTES 85 Directors and the Committees 47 6.1 Consolidated financial statements and notes 86 2.8 Other information from the corporate 6.2 Statutory Auditors’ report on the governance report contained in other consolidated financial statements 120 sections of the Registration Document 48 6.3 Annual financial statements and notes 124 6.4 Statutory Auditors’ report on the financial 3 statements 144 GUERBET AND ITS SHAREHOLDERS 49 6.5 Statutory Auditors’ special report on regulated commitments and agreements 147 3.1 Guerbet shares 49 3.2 Dividend paid over three years 50 3.3 Share ownership structure 50 7 3.4 Shareholder Agreement and collective GENERAL MEETING share lock-in commitments 51 OF MAY 25, 2018 149 3.5 Control mechanisms provided for in a 7.1 Agenda 149 potential employee shareholding system, 7.2 Draft resolutions 151 when control rights are not exercised by the employees 52 8 3.6 Threshold crossings 52 ADDITIONAL INFORMATION 161 Transactions performed by executive 3.7 8.1 Person responsible for the accuracy officers and similar individuals 52 of the Registration Document 161 Transactions performed by employees 3.8 8.2 Statutory Auditors 161 excluding company officers 52 8.3 Share capital 162 Limiting the risk of undue control 3.9 8.4 Public access to this document 162 by the majority Shareholder 54 8.5 General information about the Company 163 The Board of Directors’ powers to issue 3.10 8.6 Articles of association (excerpts) 163 and buy back shares 54 8.7 2018 Financial calendar 164 Summary of granted authorizations that 3.11 8.8 Concordance tables 165 may potentially impact the share capital 54 3.12 Provisions in the articles of association relating to the shares 54 Registration Document 2017 Including the Annual Financial Report Unofficial translation of the French language “Document de Référence 2017” of Guerbet, for information purposes only. This Registration Document was filed with the Autorité des marchés financiers or AMF (French Financial Markets Authority) on April 25, 2018, in compliance with Article 212-13 of its General Regulation. It can be used in connection with a financial transaction if it is accompanied by a securities note approved by the AMF. This Document was prepared by the issuer, and its signatories are liable for its content. In accordance with article 28 of European Regulation 809/2004 of April 29, 2004, readers are invited to refer to previous Registration Documents regarding certain information: 1. the Management Report of the Board of Directors, the consolidated financial statements and the report of the Statutory Auditors on the consolidated financial statements for the fiscal year ended December 31, 2016, included in the Registration Document filed with the AMF on April 5, 2017 under number D.17-0323; 2. the Management Report of the Board of Directors, the consolidated financial statements and the report of the Statutory Auditors on the consolidated financial statements for the fiscal year ended December 31, 2015, included in the Registration Document filed with the AMF on April 21, 2016, under number D.16-0378. A French Limited Company (société anonyme) governed by a Board of Directors with a share capital of €12,563,358 Registered Office: 15, rue des Vanesses 93420 Villepinte Bobigny Trade and Companies Register No. 308 491 521 Guerbet Registration Document 2017 1 Interview with Yves L’Épine, Chief Executive Officer 2017 confirmed the importance of Interventional Imaging for the Group’s development, alongside Diagnostic Imaging Yves L’Épine Chief Executive Officer ¢ Two years after the acquisition of CMDS, what progress made with image-guided in situ treatments (Interventional synergies are already visible? Imaging unit). The Group’s attractiveness for new talent has improved significantly on the international scene; through this successful CMDS was acquired barely two and a half years ago, and its integration, Guerbet has shown that it can combine organic growth integration into Guerbet has fundamentally changed our Group. It and growth via acquisitions. has strengthened it by adding to its range of contrast media, now well balanced with strong brands in slide X-ray imaging (Optiray®, Xenetix®) and MRI (Dotarem®), by allowing it to significantly expand ¢ How is Guerbet positioned in an MRI market marked its range of injectors and associated medical devices, by increasing its by the arrival of new generics? commercial footprint through several new affiliates and by providing The MRI segment, where Guerbet is world number 2, saw many it with plants in the United States and Ireland complementing its own events in 2017. This year, it will need to keep navigating between production facilities to meet global demand. tailwinds and headwinds. We were facing a difficult integration due to a combination of Since 2017, we have seen the introduction of a new generic in the several failure risk factors: acquisition of a company of similar size market. While Dotarem® has already faced local generic competition to ours, with declining assets, with a very different culture from for several years now, limited to a few countries in Europe and Asia, a ours, all to be handled by teams that had never been involved in new generic product was registered in 2017 in most European Union an integration process. The result is very satisfying: we are ahead countries and several Asian countries. Most of them began marketing of our value creation roadmap. Our aim was to capture more than the generic in 2017, with no significant impact on the first half of the 80% of synergies over three years, and we are already close. This year but with a slowdown in Dotarem® sales over the second half. shows the strong commitment of the employees, and I wish to pay Despite this, our growth remains strong: above 10% this year. tribute to them. The Group is now resolutely international (its sales outside France represent more than 80% of total business), and this Tailwinds are driving our flagship product, as several health agencies development has further strengthened the Group worldwide, including – in Europe, Japan, the United States and Canada – are recommending in France. We have succeeded in establishing a new common culture that, within gadolinium-based contrast media, radiologists distinguish around our primary mission of improving patient prognosis thanks between linear products and macrocyclical products according to to earlier, more precise diagnosis (Diagnostic Imaging unit) and the their safety profile, with a preference for macrocyclical products. Our 2 Guerbet Registration Document 2017 www.guerbet.com Dotarem® product, remains, nevertheless, the leader in macrocyclic ¢ How is Guerbet positioned with regard to digital products, considered to be the most stable. At the European level, development in radiology? following the decision of the EMA(1), the European Commission decided to suspend the use of non-specific linear products in human body Digital technology and artificial intelligence will transform medical imaging. In Japan, the PMDA(2) issued an order recommending the imaging profoundly by allowing quantitative data to be interpreted use of secondary linear products when macrocyclic products are not for better characterization of tissues and pathologies. Guerbet is suitable or available. Lastly, in the United States, the FDA(3) issued new particularly attentive to these developments and recruited a Chief safety measures in favor of macrocyclic products, forcing companies Digital Officer in September 2017. We are exploiting all our strengths selling MRI contrast media in the US market to change their labeling to seize any new opportunities that arise and to confirm our status as from the start of 2018. a medical imaging expert. ¢ ¢ What will be the consequence of these two trends for And how important is Interventional Imaging’s role? Guerbet? Very important! Our strategy to strengthen Interventional Imaging has already been in place for several years and is continuing. Our Lipiodol® The long-term result of these two trends is not clear yet, but they and Patent Blue V products are recognized as gold standards: the first are not preventing our double-digit growth in this segment for now. in transarterial chemoembolization of liver cancers and the second We have prepared an industrial plan to significantly increase our in the detection of sentinel nodes in breast cancer.
Recommended publications
  • ANNEX a Economic Development Board's Industry Highlights The
    ANNEX A Economic Development Board’s Industry Highlights The Economic Development Board, together with its partner agencies the Infocomm Development Authority and the Media Development Authority, aims to make Singapore the region’s media hub. The intention is to promote Singapore as a compelling location for media companies across the entire industry value chain; creating a self-reinforcing, inter-dependent ecosystem that will continuously attract talent, ideas, capital and enterprises to create international products and services from Singapore. Singapore's vision to become the region’s media hub, combining both production and regional business responsibilities, is being realised with enterprises setting up, expanding and extending their operations in Singapore. With our technological capabilities and global reach, Singapore is primed to develop the media industry into an unparalleled success. Below are examples of international companies with presence in Singapore spanning across the Publishing & Information Services, Broadcast & Production and Games & Animation sectors. Page 1 of 4 PUBLISHING & INFORMATION SERVICES Wiley Services Singapore Established in 2005, this is the first publishing services project in Singapore on a global scale, and also from the world's number 3 Scientific, Technical and Medical (STM) & Academic Journal publisher Wiley-Blackwell. Wiley Services Singapore was established as the Global Publishing Services HQ to support all Blackwell Publishing entities globally in the area of journals and books printing & distribution, customer services, IT support and production management. Ink Publishing Pte Ltd Established in 2006, Ink Publishing from UK is the world’s leading in-flight magazine publisher, with titles that include Bangkok Airways Fah Thai, Cebu Pacific Smile, China Airlines Sky Boutique, China Airlines Sky Couch, Jetstar Airways Jetstar, Siem Reap International Airways Sarika and Tiger Airways Tiger Tales.
    [Show full text]
  • February 25, 1871, Vol. 12, No
    : xtmtlt HUNT'S MERCHANTS' MAGAZINE, REPRESENTING THE INDUSTRIAL AND COMMERCIAL INTERESTS OF THE UNITED STATEa VOL. 12. NEW YORK, FEBRUARY 25, 1871. NO; 296. ^bocrtiecmcnta. Bankers and Br.' kers. Bankers and Brokers. B. B. Ferrill & Co., Dodge, Kimball Adrgrtlnmsnta will be tosertMl «t th* foUawlBg & Moore rlo«» per Une lor each liuertloa Gonunlasloo Slercbaiita ft Brokers, BANKERS, <i ordered leH tbui 4 time*. Weenta per Une. STOCK AND GOLD BBOKERS. « . Imeeormote 1< " BAVAKSAH, GA. r " U " " And dealers In > W - U WUl glre strict personal attention to all bnslneas '. M W •• " entrusted to them. Consignments respectfully soUcl- GOTERNnENT SEOVBITIBS, II a 8 " ted. 14 WALL STREET. N. T. It the edTerttBement occnples one oolaoin or np- Collections promptly remitted. warJe, e dlwuuot of IS per cent on thew rates wUl be P. O. Box 4,306. ellowed. Sptce Is meuored In sgsM type, 14 Uses to the A. C. Kaufman, :uoa. Duncan, Sherman & Co., AdTertlaoraonts will have a favorable place when BANKEB & BROKER, rst put lu, but no promise of oontmuoos Iniiiirtiun In No. 11 Nassan St., New Tork Oltr, be best plHcu can be Klven, as all advertisers must OHABLESTON, S. O. ttve equal opportunities. DSALS RxeOLARLV IK TDK FOLLOWINa LlNX OF ISSUE CIRCDXAR NOTES AND CIRCULAB DSSISABLS SOUTUSBN SjlOITBlTZSS, TIZ.: Letters or Credit available and payable In all tha PRINCIPAL CITIES ; also In the _ South Curolina SUte Bonds; Charleston City OF THE WOULD Stock Onlted States, Canada and West Indies. 1. The CHROKICLK has much the largest clronla- : Savannah City Bonds; Augusts City Bonds; ilan Memph a v of any ODanclal publication iaauea.
    [Show full text]
  • Mri Contrast Medium and Diagnostic Method
    Europa.schesP— || | MMMMI 1 1||||| 1 1 1 1 1 1||| || J European Patent Office _ o it r- a 4 © Publication number: 0 673 655 A1 Office_„. europeen des brevets © EUROPEAN PATENT APPLICATION published in accordance with Art. 158(3) EPC © Application number: 93906789.8 © Int. CI.6: A61 K 49/00 @ Date of filing: 18.03.93 © International application number: PCT/JP93/00322 © International publication number: WO 93/18795 (30.09.93 93/24) ® Priority: 19.03.92 JP 93561/92 Kanagawa 211 (JP) Inventor: IWAI, Hlroyuki, Yodogawa Works of @ Date of publication of application: Daikin Ind.Ltd.s 27.09.95 Bulletin 95/39 1-1, Nlshlhltotsuya Settsu-shl, © Designated Contracting States: Osaka 566 566 (JP) DE FR GB IT Inventor: YAMASHITA, Tsuneo, Yodogawa Works © Applicant: DAIKIN INDUSTRIES, LIMITED of Daikin Ind. Ltd., Umeda Center Building, 4-12, Nakazaki-nishi 1-1, Nishihitotsuya 2-chome Settsu-shi, Kita-ku Osaka 566 566 (JP) Osaka-shi Inventor: SHIMOKAWA, Kazuhiro, Yodogawa Osaka 530 (JP) Works of Daikin Ind. Ltd., © Inventor: YOSHIKAWA, Kohki 1-1, Nishihitotsuya 14-23, Kami-saginomiya 5-chome, Settsu-shi, Nakano-ku Osaka 566 (JP) Tokyo 165 (JP) Inventor: SHIONO, Takahiro, Kanto Rohsai Hospital © Representative: TER MEER - MULLER - 2035, Kizuki Sumiyoshi-cho, STEINMEISTER & PARTNER Nakahara-ku Mauerkircherstrasse 45 Kawasaki-shi, D-81679 Munchen (DE) ^ © MRI CONTRAST MEDIUM AND DIAGNOSTIC METHOD. in m CO © An MRI contrast medium (suspension) comprising an oily fatty acid, fatty acid ester or perfluorinated compound and a particulate paramagnetic compound contained therein. It can be used stably for long and can ^ be administered to a target region, whereby its dose can be reduced.
    [Show full text]
  • Caracterización Fisicoquímica Y Clínica De Los Medios De Contraste Intravasculares Iodados
    Anales de Radiología México 2008;2:129-140. ARTÍCULOS DE REVISIÓN Dra. Patricia Rodríguez Nava,1 Dr. Ernesto J. Dena Espinoza,1 Caracterización fisicoquímica y Dr. Roberto Basile Lenge,2 Dra. Margarita Fuentes García,3 clínica de los medios de contraste Dr. Gustavo Fink Josephi,4 Dr. Eduardo Marbez Namnum1 intravasculares iodados RESUMEN Objetivo: El propósito de sido aceptado por algunos ra- este artículo es realizar una re- diólogos. La lopromida puede Introducción: El uso de visión bibliográfica sobre las ca- ser considerada un agente uni- medios de contraste intravascu- racterísticas, clasificación, pro- versal para todas las explora- lares no iónicos (gas, sustancia piedades físico-químicas, así ciones y procedimientos radio- hidrosoluble o liposoluble) en como los efectos secundarios lógicos. imagenología ha proliferado (quimiotoxicidad) de los medios en los últimos años debido a su de contraste intravasculares no Palabras clave: Medios de excepcional tolerancia por los iónicos. contraste intravasculares ioda- pacientes. La baja osmolalidad Conclusiones: Un factor que dos, medios de contraste ióni- de este tipo de medios de con- interviene en la incidencia de cos, medios de contraste no ió- traste aporta beneficios como reacciones idiosincráticas o aler- nicos. bajo incremento del volumen goides puede ser el estado psi- sanguíneo, baja toxicidad, bajo cológico del paciente. El trata- efecto sobre la barrera hema- miento previo con antihitamíni- toencefálica. cos, corticosteroides o ambos ha continúa en la pág. 130 1 Del Servicio de Radiología e Imagen “Dr. Carlos Coqui” del Hospital General de México osmolalidad o iso-osmolares. En los Estados Unidos 2 3 O.D. De la Universidad de Buenos Aires Cardiología.
    [Show full text]
  • A034047-100 Top Secrets.Qxd 5/18/06 2:32 PM Page 1
    A034047-100 Top Secrets.qxd 5/18/06 2:32 PM Page 1 TOP 100 SECRETS These secrets are 100 of the top board alerts. They summarize the concepts, principles, and most salient details of CT body scans. 1. Computed tomography (CT) differs from conventional radiography by forming a cross-sectional image, eliminating the superimposition of structures that occurs in plain film imaging because of compression of three-dimensional body structures onto the two-dimensional recording system. 2. The sensitivity of CT to subtle differences in x-ray attenuation is at least a factor of 10 higher than normally achieved by film screen recording systems because of the virtual elimination of scatter. 3. Radiation doses in CT range from 15–50 mGy, depending on exam type. In general, these doses are at least 10 times higher than in radiographic exams. 4. Always seek to optimize scan parameters to minimize patient dose consistent with diagnostic image quality: Minimize mAs, minimize kVp, maximize pitch, maximize slice thickness, and maximize collimator setting. 5. When scanning children, be sure to use pediatric protocols, not adult protocols. In pediatric protocols the CT scan parameters should be reduced so that radiation doses are optimized according to patient size. 6. Pregnant women should be scanned only if there is adequate justification to avoid unnecessary fetal irradiation. 7. Many of the side effects of contrast media are entirely or mainly due to high osmolality. The other causes of side effects due to contrast media are chemotoxicity (allergic-like symptoms), ion toxicity (interference with cellular function), and those caused by a high dose.
    [Show full text]
  • Half Year Report 2019
    Half-year results for the six months period ending June 30, 2019 Ticker symbol : NWAY 1 | Nexway: Half-year results 2019 www.nexway.com Management report on the situation of the group for the first half of 2019 GENERAL INFORMATION ABOUT THE GROUP Corporate structure and business model Nexway AG (formerly asknet AG) is a leading ecommerce and payment service provider. Combining technology and managed services, the Nexway Group offers solutions to software, video games, services, digital marketplaces and retail companies to run and maximize their online sales worldwide, serving companies across 180 countries around the world. By using state-of-the-art technology, a full range of industry-leading ecommerce and payment solutions and a hands-on team of industry experts, Nexway is servicing online businesses to scale, grow and thrive in today’s global sales marketplace. More specifically, Nexway clients leverage subscription models, local payment methods, fraud prevention, partner & reseller management and customer insights to transform their purchasing experience and grow their business. The company also provides software procurement and distribution services to European academic institutions, students and alumni. The company is based in Karlsruhe and Paris La Défense, with offices in the US, Japan, Italy, Poland and Switzerland. Nexway AG shares are listed and traded on the Frankfurt Stock Exchange. The identity of Nexway is based on technology and top-quality customer service. The group is dedicated to innovation and is proud of its role as a global pioneer of API-driven, headless commerce architectures. The benefits of Nexway’s technical innovation is what both makes the solutions agile and allows our customers to scale and grow their online businesses fast.
    [Show full text]
  • Structure and Properties of X-Ray Contrast Media
    STRUCTURE AND PROPERTIES OF X-RAY CONTRAST MEDIA Optimal use of CM in radiology requires a knowl- edge of the nature and relevant properties of the available substances. This chapter describes the properties of currently used and newly developed contrast-giving agents that infuence their behav- ior in the human body, their side effects, and their practical utility. The main X-ray contrast agents in use today are insoluble barium sulfate for the diagnostic evalu- ation of the GI tract and water-soluble CM for the radiological assessment of the different vascular systems, body cavities and organs. In addition, a water-soluble CM based on tri-iodobenzene is the alternative agent of choice for oral use when bari- um sulfate is contraindicated. Barium Sulfate Barium is used in the form of the insoluble sulfate for radiography of the GI tract. If perforation is suspected, however, only water-soluble, iodinated agents (Gastrografn, Ultravist-370) can be used since the body is virtually incapable of eliminating barium sulfate once it has entered the peritoneum. Barium sulfate is available either as a powder to be prepared directly before use or as a ready-to-use suspension. For double-contrast examinations (fll- ing of the lumen with gas, coating of the wall with barium sulfate), barium sulfate is either mixed with a carbon dioxide additive, or a gas-forming agent is taken in addition. © The Author(s) 2018 20 U. Speck, X-Ray Contrast Media, https://doi.org/10.1007/978-3-662-56465-3_3 Common to all barium preparations is concentra- tion of barium sulfate which may diluted according to the needs of the examination.
    [Show full text]
  • The Only Oil-Based Contrast Agent Indicated for HSG1-9
    Ethyl ester of iodized fatty acids of poppy seed oil The only oil-based contrast agent indicated for HSG 1-9 INFERTILITY EVALUATION TUBAL UTERINE IMAGING IMAGING FOR HYSTEROSALPINGOGRAPHY Pharmaceutical form: Lipiodol® Ultra Fluid 480 mg Iodine per mL, solution for injection 10 mL - ethyl esters of iodized fatty acids of poppy-seed oil Posology/Recommended dosage: Up to 20 mL, depending on the volume of the uterine cavity 2-3 P 4 Lipiodol® Ultra Fluid for Hysterosalpingography (HSG) P 5 Reasons for performing HSG P 6 The female reproductive system P 7 When to perform HSG P 8 HSG steps P 9 Lipiodol® HSG: Findings P 10 Lipiodol® HSG: Endorsement by international clinical practice guidelines P 11 Lipiodol® HSG: Safety P 12 Lipiodol® HSG: Pain P 13 Lipiodol® HSG: Features & Benefits P 14 Bibliography Lipiodol® Ultra Fluid for Hysterosalpingography ( ) Hysterosalpingography: radiological examination to investigate the uterine cavity, Fallopian tubes & peritoneal cavity. It entails the injection of contrast medium and visualization under fluoroscopy. 10 CHARACTERIZATION OF HSG FINDINGS: Tubal abnormalities Uterine cavity abnormalities Tubal occlusion Congenital anomalies Salpingitis isthmica nodosum Polyps Polyps Leiomyomas Hydrosalpinx Surgical changes Peritubal adhesions Synechiae Adenomyosis Müllerian duct anomalies Source: Simpson WL Jr et al. Hysterosalpingography: a reemerging study. Radiographics. 2006 Mar-Apr;26(2):419-31. - Simple & accurate procedure for tubal patency & uterine investigation 4-5 Lipiodol® Ultra Fluid for Hysterosalpingography
    [Show full text]
  • Mh, Thte Post Wsak.'Wmeh Briars Tol C a Te
    EAimDATUAfM' Lend to End the Warjr^Bu^ A s As You Can! I »i^ ««—"■»«»» club will (^urch Parley bold a sotbank party la tho TJm ^ ibeMolaylBrop I Heard Along Main Street itTown Hgtniittiy St 8:U tonight. Bvoi^ Average Dally drcuhtioR m la wdoomo. RafraohmanU win L ^ f u l o n Somm o f Manehe$tmt^9 Sidm S treets, Ttfo Memorial Day rvw.tts Msath sC Apia, 1H3 bo aorrod. ____ Well Attended The Weather r«( «tiU*6 Orgaalsod ia Bwtamber of 1940,1 il CMton of A number of the local nills, tap^law.__________ In one or two «wtaarethe NaESFene to Act as the 7,327 s f D. a . WsbOm ________ I ia tlM lU ^ k o Chanibor at OOnuDOreo AUxl^l- Anniial Spring Social rooms and restauranU have Just purchaser stood to lose heavily the ^.ES t at TdN> Monday «v»- isry. whoso drst president ^ found out that they are liable to a sonlng board members have been Post to Churches in $200 IN . « i tho noaot M- Mrs. Joseph Poro, will glw the Is Held Am id a Patri-| tax under a law that went into ef­ lenient and aUosred the changes. oa la RMdta«, Pa^ fifth’ in its series of welcoming fect last October if they have Juke But it has happeiMd too often now Connecticut Valley. Ibart win ba a teas to a largo number of the otic Setting. boxes and a dancing space. ’The and real estate salesmen had best h e. M anchester A CUy o f ViOage^Chsarm ftOoarlar tho aMotliiff.
    [Show full text]
  • WO 2017/142292 Al
    /OA (12) 특허협력 조약에 의하여 공개된 국제출원 (19) 세계지 식재산권기구 국제사무국 (10) 국제공개번호 (43) 국제공개일 WO 2017/142292 A l 2017 년 8 월 24 일 (24.08.2017) W Ο P C T (51) 국제특허 분류: Incheon (KR). 최병현 (CHOI, Byeong-Hyeon); 08308 서 0 67/(927 (2006.01) G01N 33/50 (2006.01) 울 시 구로구 구로동로 148, 연구동 2 층 흉부 외과 연구 실, Seoul (KR). (21) 국제출원번호: PCT/KR2017/001610 (74) 대 리 인 : 특 허 법 인 충 현 (CHUNG HYUN PATENT (22) 국제출원일: 2017 년 2 월 14 일 (14.02.2017) LAW FIRM); 06779 서울 시 서초 구 동산로 23 베 델 회 (25) 출원언어 : 한국어 관 8 층, Seoul (KR). (26) 공개언어 : (81) 지정국 ( 별도 의 표 시가 없는 한 , 가능한 모든 종류의 국 내 권 리 의 보 호 를 위 하 여 ) : AE, AG, AL, AM, AO, (30) 우선권정보: AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 10-2016-0017226 2016 년 2 월 15 일 (15.02.2016) K R CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, 년 월 일 10-2017-00193 12 2017 2 13 ^13.02.2017; K R DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (71) 출원인: 고 려대학교 산학협력단 (KOREA UNIVER HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, SITY RESEARCH AND BUSINESS FOUNDATION) KP, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, [KR/KR]; 0284 1 서 울 시 성 북 구 안 암 로 145, Seoul ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, CM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, (KR).
    [Show full text]
  • Appendix B - Product Name Sorted by Applicant
    JUNE 2021 - APPROVED DRUG PRODUCT LIST B - 1 APPENDIX B - PRODUCT NAME SORTED BY APPLICANT ** 3 ** 3D IMAGING DRUG * 3D IMAGING DRUG DESIGN AND DEVELOPMENT LLC AMMONIA N 13, AMMONIA N-13 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18 3M * 3M CO PERIDEX, CHLORHEXIDINE GLUCONATE * 3M HEALTH CARE INC AVAGARD, ALCOHOL (OTC) DURAPREP, IODINE POVACRYLEX (OTC) 3M HEALTH CARE * 3M HEALTH CARE INFECTION PREVENTION DIV SOLUPREP, CHLORHEXIDINE GLUCONATE (OTC) ** 6 ** 60 DEGREES PHARMS * 60 DEGREES PHARMACEUTICALS LLC ARAKODA, TAFENOQUINE SUCCINATE ** A ** AAA USA INC * ADVANCED ACCELERATOR APPLICATIONS USA INC LUTATHERA, LUTETIUM DOTATATE LU-177 NETSPOT, GALLIUM DOTATATE GA-68 AAIPHARMA LLC * AAIPHARMA LLC AZASAN, AZATHIOPRINE ABBVIE * ABBVIE INC ANDROGEL, TESTOSTERONE CYCLOSPORINE, CYCLOSPORINE DEPAKOTE ER, DIVALPROEX SODIUM DEPAKOTE, DIVALPROEX SODIUM GENGRAF, CYCLOSPORINE K-TAB, POTASSIUM CHLORIDE KALETRA, LOPINAVIR NIASPAN, NIACIN NIMBEX PRESERVATIVE FREE, CISATRACURIUM BESYLATE NIMBEX, CISATRACURIUM BESYLATE NORVIR, RITONAVIR SYNTHROID, LEVOTHYROXINE SODIUM ** TARKA, TRANDOLAPRIL TRICOR, FENOFIBRATE TRILIPIX, CHOLINE FENOFIBRATE ULTANE, SEVOFLURANE ZEMPLAR, PARICALCITOL ABBVIE ENDOCRINE * ABBVIE ENDOCRINE INC LUPANETA PACK, LEUPROLIDE ACETATE ABBVIE ENDOCRINE INC * ABBVIE ENDOCRINE INC LUPRON DEPOT, LEUPROLIDE ACETATE LUPRON DEPOT-PED KIT, LEUPROLIDE ACETATE ABBVIE INC * ABBVIE INC DUOPA, CARBIDOPA MAVYRET, GLECAPREVIR NORVIR, RITONAVIR ORIAHNN (COPACKAGED), ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE
    [Show full text]
  • Super-Selective Transarterial Chemoembolization With
    Balli, H, et al. Super-Selective Transarterial Chemoembolization with Doxorubicin-Loaded Drug-Eluting Beads Sized Below and Above 100 Microns in Hepatocellular Carcinoma: A Comparative Study. Journal of the Belgian Society of Radiology. 2019; 103(1): 47, 1–7. DOI: https://doi.org/10.5334/jbsr.1841 ORIGINAL ARTICLE Super-Selective Transarterial Chemoembolization with Doxorubicin-Loaded Drug-Eluting Beads Sized Below and Above 100 Microns in Hepatocellular Carcinoma: A Comparative Study Huseyin Balli, Erol Aksungur, Behruz Khalatai and Kairgeldy Aikimbaev Objectives To compare efficacy and safety of super-selective DEB-TACE with doxorubicin-loaded micro- spheres sized below and above 100 microns for treatment of hepatocellular carcinoma (HCC). Material and methods All consecutive patients with HCC who underwent DEB-TACE were included in this retrospective study. Regarding to microsphere size (>100 microns or <100 microns), patients were determined as Group A (n = 28) and Group B (n = 30), respectively. Results Of the 58 patients (78% males), no statistically sig- nificant difference was found between the two groups in terms of age and gender (P = 0.388, P = 0.888, respectively). There were no significant differences between the two groups in terms of BCLC stages, presence of chronic liver disease, and Child-Pugh classes (P = 0.593, P = 0.081, P = 0.391, respectively). Although statistically insignificant, median overall survival (19 months vs 32 months, P = 0.190) and median progression-free survival (13 months vs 20 months (P = 0.574) were longer and 1-3-years objec- tive response rates (7.40% vs 23.33%, P = 0.330) were higher in Group B than in Group A, respectively.
    [Show full text]